Skip to main content
OpenTrials
Completed

NCT Number: NCT04343586

Blue Light Phototherapy

This study will use Blue-light Photo-therapy to treat patients with psoriasis vulgaris and Grover's Disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Grover's Disease Psoriasis Vulgaris

Age range

18 year–89 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Northwestern University Department of Dermatology

Chicago, Illinois, 60611, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient's aged 18-89 at time of enrollment
  • Previous diagnosis of psoriasis vulgaris or Grover's disease

Exclusion criteria

  • All Groups: Subjects who are younger than 18 years of age or older than 90 years of age
  • Patients who have received topical or systemic treatment within the prior 2 weeks of planned phototherapy
  • Patients prescribed any of the following drugs for issues not related to their psoriasis or Grover's disease
  • topical steroids
  • calcineurin inhibitors
  • methotrexate
  • retinoids
  • biologic agents
  • Unable to schedule phototherapy sessions
  • We will not recruit the following populations: adults unable to consent, individuals who are not yet adults (infants, children, teenagers), pregnant women, prisoners and other vulnerable populations.

Treatment and study plan

Blue Light Phototherapy

Device

Phototherapy- Wavelength: 417±15 nm

Other names: DusaPharma Blu-U model 4170

Primary outcomes

  1. Efficacy of Blue Light Therapy for Patients With Grover's Disease

    Time frame: Time Frame: 5 weeks

    Demonstrate preliminary skin efficacy as measured by lesion count

  2. Assess User Experience With the Dermatology Life Quality Index (DLQI) Pre and Post-treatment.

    Time frame: Time Frame: 5 weeks

    The DLQI is a questionnaire with 10 questions. The maximum score is 30 and minimum is 0. The higher the score, the more quality of life is impaired.

Sponsors and collaborators

Lead sponsor

Northwestern University

Other

Collaborators

  • T-Cellerate LLC

Registry information

Official study title

Development & Preliminary Clinical Validation Blue Light Phototherapy Systems for T-Cell

Important dates

Study start
2020
Primary completion
2021
Study completion
2022
First posted
Apr 13, 2020
Registry last updated
Mar 17, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.